Dr. Reddy’s arm inks commercialization and license agreements for biosimilars

27 Mar 2025 Evaluate

Dr. Reddy’s Laboratories’ wholly-owned subsidiary -- Dr. Reddy’s Laboratories SA and Bio-Thera Solutions have reached commercialization and license agreements for BAT2206, a Proposed Stelara Biosimilar, and BAT2506, a Proposed Simponi Biosimilar. Bio-Thera Solutions is a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars.

Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506. Dr. Reddy’s will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, Vietnam. In addition, Dr. Reddy’s will also receive the exclusive commercial rights to BAT2206 in Colombia.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1144.05 -18.30 (-1.57%)
28-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...